Uterine fibroids are steroid hormone-dependent tumors of the ovary, and estrogen and progesterone receptors are found in fibroid tissues, which are significantly higher than those in uterine muscle tissue. Numerous studies have shown that the content of estrogen receptors in fibroids is proportional to the growth rate of fibroids, and estrogen can also stimulate the proliferation of fibroids. Based on the above theory, the application of preparations that inhibit the secretion of ovarian steroid hormones or their effects can reduce the size of fibroids and alleviate the symptoms. However, it is generally not possible to eliminate and cure the fibroids, and there is often a possibility of recurrence and re-growth of fibroids with the recovery of sex hormone levels in the body after stopping the drugs. Therefore, the indications for these drugs for the treatment of fibroids include: (1) those who have fertility requirements; (2) those who are near menopause; (3) those who want to reduce bleeding and increase hemoglobin level before surgery; (4) those who want to shrink fibroids before surgery to reduce intraoperative bleeding and shorten surgery time; (5) those who want to undergo transvaginal hysterectomy or hysteroscopic laparoscopic treatment. Gonadotropin-releasing hormone antagonist (GnRHa) produces Follicle-stimulating hormone (FSH) and luteinizing hormone (LH). Luteinizing Hormone (LH), lowering estradiol to menopausal levels, thereby relieving symptoms and inhibiting the growth and shrinkage of fibroids. The commonly used drugs are leuprolide, goserelin and treprostinil. At present, they are mostly used in clinical practice: (1) preoperative adjuvant treatment for 3-6 months, after controlling symptoms, correcting anemia and shrinking fibroids, to reduce the difficulty of surgery, reduce intraoperative bleeding and avoid blood transfusion; (2) early transition to natural menopause for patients with near menopause. Mifepristone Mifepristone exerts its antitumor effect mainly through the following channels: (1) directly counteracting progesterone activity or inhibiting PR gene expression; (2) inhibiting epithelial growth factor gene expression in fibroid tissues; (3) reducing uterine artery blood flow. The duration of vaginal bleeding was significantly reduced and the hemoglobin level increased after taking mifepristone 50 mg once every other day for 3 months. There was no significant change in serum cortisol level and a slight increase in androgen level. Endometrial biopsy showed no precancerous lesions after the administration of the drug. Thus, mifepristone is a safe and effective drug in the treatment of uterine fibroids and is now commonly used in clinical practice. TMX (tamoxifen, TMX) acts on the pituitary gland, which in turn affects the ovaries, and also has a direct effect on the ovaries. There are reports in the literature that triamcinolone acetonide alone is not as effective in the treatment of uterine fibroids, and that triamcinolone acetonide has weak estrogenic effects and can induce endometrial cancer in individual patients with long-term application. Theoretically, this combination is a combination of anti-estrogen and progesterone chemotherapy, which should be a more ideal treatment method. Other drugs Androgen derivatives (19 norethindrone derivative-pregnantrienone and 17A-ethinyl testosterone derivative-danazol) and androgenic drugs (methyltestosterone, testosterone propionate). The direction of drug therapy Although all of these drugs are clinically used and have achieved some therapeutic effect, none of them, except for GnRHa, are included in the indications for uterine fibroids in the manual. Only GnRHa is approved by FDA for the treatment of uterine fibroids to correct the symptoms of bleeding and anemia caused by fibroids. The future direction of drug therapy for uterine fibroids is to block the action of growth factors that regulate cell proliferation and collagen production. While normal uterine smooth muscle has little or no aromatase enzyme that converts circulating androgens into estrogen, fibroids express this enzyme in situ in the fibroids, thus allowing them to grow fully. The larger the fibroid, the greater the expression of this enzyme. Therefore, in order to avoid the systemic hypoestrogenic symptoms associated with conventional drug therapy, research into drugs that inhibit this aromatase without affecting normal ovarian function is the mainstay of current research.